Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

This publication has 37 references indexed in Scilit:

• Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies
  Journal of Cancer Policy, 2014
• Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
  Annals of Oncology, 2013
• The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
  Blood, 2013
• NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
  The Lancet Oncology, 2012
• Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
  Clinical Lymphoma Myeloma and Leukemia, 2010
• InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
  Blood, 2010
• Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
  Blood, 2010
• Targeted therapy in haematological malignancies
  The Journal of Pathology, 2009
• Closing the gap: Cancer in Central and Eastern Europe (CEE)
  European Journal of Cancer, 2008
• Non-Hodgkin lymphoma: an update
  The Lancet Oncology, 2004